Anda Militaru1, Adina Avram1, Anca Maria Cimpean2, Mircea Iurciuc3, Petru Matusz4, Daniel Lighezan1, Marius Militaru5. 1. Medical Semiology I, Department of Internal Medicine I, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. 2. Department of Microscopic Morphology/Histology, Angiogenesis Research Center, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania ancacimpean1972@yahoo.com. 3. Department of Cardiology, Preventive Medicine and Cardiovascular Rehabilitation, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. 4. Department of Anatomy and Embryology, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. 5. Neurology, Department of Neuroscience - Municipal Emergency Hospital, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.
Abstract
Aim To assess the onset of early left ventricular (LV) systolic and diastolic function impairment and the subclinical atherosclerosis following chemotherapy in patients diagnosed with acute myeloid leukemia (AML). MATERIALS AND METHODS: Thirty patients diagnosed with AML with no cardiac history, having LV ejection fraction (LVEF) >50%, were evaluated at baseline and 6 months after starting four cycles of chemotherapy. We measured LV function, global longitudinal strain and subclinical atherosclerosis markers: intima-media thickness (IMT), arterial stiffness aortic pulse wave velocity (PWVAo) and ankle-brachial index (ABI). RESULTS: LVEF had decreased at 6 months after treatment initialization (p<0.001), the same changes being observed for LV fraction shortening (p<0.001), mitral annular plane systolic excursion and S' wave (p<0.001 and p<0.05). Bilateral IMT and PWVAo significantly increased, 12 out of 30 patients (40%) had LVEF ≤50% after 6 months of chemotherapy, five of them receiving daunorubicin at more than 500 mg/m2/injection. CONCLUSION: LV function is impaired after 6 months of chemotherapy, with early changes of subclinical atherosclerosis becoming evident. Copyright
Aim To assess the onset of early left ventricular (LV) systolic and diastolic function impairment and the subclinical atherosclerosis following chemotherapy in patients diagnosed with acute myeloid leukemia (AML). MATERIALS AND METHODS: Thirty patients diagnosed with AML with no cardiac history, having LV ejection fraction (LVEF) >50%, were evaluated at baseline and 6 months after starting four cycles of chemotherapy. We measured LV function, global longitudinal strain and subclinical atherosclerosis markers: intima-media thickness (IMT), arterial stiffness aortic pulse wave velocity (PWVAo) and ankle-brachial index (ABI). RESULTS: LVEF had decreased at 6 months after treatment initialization (p<0.001), the same changes being observed for LV fraction shortening (p<0.001), mitral annular plane systolic excursion and S' wave (p<0.001 and p<0.05). Bilateral IMT and PWVAo significantly increased, 12 out of 30 patients (40%) had LVEF ≤50% after 6 months of chemotherapy, five of them receiving daunorubicin at more than 500 mg/m2/injection. CONCLUSION: LV function is impaired after 6 months of chemotherapy, with early changes of subclinical atherosclerosis becoming evident. Copyright
Authors: Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Timothy C Tan; Victor Cohen; Jose Banchs; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: Circ Cardiovasc Imaging Date: 2012-06-28 Impact factor: 7.792
Authors: Kazuaki Negishi; Tomoko Negishi; Brian A Haluska; James L Hare; Juan Carlos Plana; Thomas H Marwick Journal: Eur Heart J Cardiovasc Imaging Date: 2013-09-20 Impact factor: 6.875
Authors: Katarzyna Mizia-Stec; Adrianna Gościńska; Magdalena Mizia; Maciej Haberka; Artur Chmiel; Wojciech Poborski; Zbigniew Gąsior Journal: Kardiol Pol Date: 2013 Impact factor: 3.108
Authors: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield Journal: Blood Date: 2009-10-30 Impact factor: 22.113
Authors: Ruxandra Jurcut; Hans Wildiers; Javier Ganame; Jan D'hooge; Robert Paridaens; Jens-Uwe Voigt Journal: Support Care Cancer Date: 2008-01-16 Impact factor: 3.603
Authors: Kazuaki Negishi; Tomoko Negishi; James L Hare; Brian A Haluska; Juan Carlos Plana; Thomas H Marwick Journal: J Am Soc Echocardiogr Date: 2013-04-03 Impact factor: 5.251
Authors: Brandon C Drafts; Katie M Twomley; Ralph D'Agostino; Julia Lawrence; Nancy Avis; Leslie R Ellis; Vinay Thohan; Jennifer Jordan; Susan A Melin; Frank M Torti; William C Little; Craig A Hamilton; W Gregory Hundley Journal: JACC Cardiovasc Imaging Date: 2013-05-01
Authors: Shannon K Parr; Jia Liang; Keri L Schadler; Susan C Gilchrist; Catherine C Steele; Carl J Ade Journal: J Am Heart Assoc Date: 2020-07-10 Impact factor: 5.501